Mosaic ImmunoEngineering Inc

For the period ended Dec 31, 2023. Filed Apr 15, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Apr 15, 2024

CPMVStored price and day change unavailable

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets

	December 31, 2023	December 31, 2022
ASSETS
Current assets:
Cash and cash equivalents	$156,178	$220,645
Prepaid expenses and other current assets	23,355	40,632
Total current assets	179,533	261,277
Total assets	$179,533	$261,277
LIABILITIES AND STOCKHOLDERS’ DEFICIT
Current liabilities:
Accounts payable	$118,478	$133,464
Derivative liability	–	46,700
Accrued compensation	3,184,911	2,399,132
Accrued consulting	787,903	753,570
Accrued expenses and other	641,763	584,808
Total current liabilities	4,733,055	3,917,674
Convertible notes, net	1,317,536	1,228,361
Total liabilities	6,050,591	5,146,035
Commitments and contingencies	–	–
Stockholders’ deficit:
Preferred stock, $0.00001 par value; 5,000,000 shares authorized:
Series A Convertible Voting Preferred Stock; 630,000 shares designated; no shares issued and outstanding	–	–
Series B Convertible Voting Preferred Stock; 70,000 shares designated; 70,000 shares issued and outstanding	1	1
Common stock, $0.00001 par value: 100,000,000 shares authorized: 7,242,137 shares issued and outstanding	72	72
Additional paid-in capital	2,045,206	2,023,271
Accumulated deficit	(7,916,337)	(6,908,102)
Total stockholders’ deficit	(5,871,058)	(4,884,758)
Total liabilities and stockholders’ deficit	$179,533	$261,277

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.